Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Locations: - Veterans Administration Medical Center - Birmingham — Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
+ 1226 more sites in the U.S.
Phase 2, Phase 3 Recruiting Network
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Locations: - Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
+ 383 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Locations: - NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- Tower Cancer Research Foundation — Beverly Hills, California
- Kaiser Permanente Dublin — Dublin, California
+ 263 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
+ 259 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Locations: - Local Institution - 007-556-A — Goodyear, Arizona
- USOR - Arizona Oncology - Prescott Valley — Prescott Valley, Arizona
- Local Institution - 007-568-A — Safford, Arizona
+ 217 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Locations: - Alabama Oncology, Shelby — Alabaster, Alabama
- Alabama Oncology, Bessemer — Bessemer, Alabama
- Alabama Oncology, St Vincent's Birmingham — Birmingham, Alabama
+ 194 more sites in the U.S.
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Locations: - Clinical Study Site — Chandler, Arizona
- Clinical Study Site — Phoenix, Arizona
- Clinical Study Site — Hot Springs, Arkansas
+ 91 more sites in the U.S.
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Locations: - Clearview Cancer Institute — Huntsville, Alabama
- Infirmary Cancer Care — Mobile, Alabama
- City of Hope, Phoenix — Phoenix, Arizona
+ 85 more sites in the U.S.
Phase 3 Recruiting Industry
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…
Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Locations: - Clinical Research Advisors, LLC — Beverly Hills, California
- Clinical Research Advisors - Encino — Encino, California
- Clinical Research Advisors - West Hollywood — Los Angeles, California
+ 76 more sites in the U.S.
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Locations: - Local Institution - 0347 — Birmingham, Alabama
- Local Institution - 0686 — Springdale, Arkansas
- Local Institution - 0581 — Fullerton, California
+ 49 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/…
Sponsor: OncoC4, Inc.
NCT ID: NCT05671510
Locations: - XCancer/Dothan Hematology & Oncology - 1114 — Dothan, Alabama
- Genesis Cancer and Blood Institute - 1123 — Russellville, Arkansas
- The Oncology Institute (TOI) Clinical Research - 1109 — Cerritos, California
+ 43 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …
Sponsor: Pfizer
NCT ID: NCT07226999
Locations: - Highlands Oncology Group — Fayetteville, Arkansas
- Highlands Oncology Group — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
+ 42 more sites in the U.S.